Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.87 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.87 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PARG | Q86W56 | 1/20 | 0.45 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28820135 | 0.91 | ALDH1A1 (0.97) | ALDH1A1L3MBTL1HTR1AHTR7MAPT | |
| SCHEMBL4031272 | 0.86 | ALDH1A1 (0.66) | ALDH1A1L3MBTL1HTR1AHTR7MAPT | |
| SCHEMBL2356839 | 0.80 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1HTR1AHTR7MAPT | |
| SCHEMBL10453953 | 0.80 | ALDH1A1 (0.77) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL4036979 | 0.79 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1MAPTKMT2AGAA | |
| SCHEMBL2372258 | 0.79 | HDAC8 (0.57) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL6216811 | 0.78 | MAPT (0.56) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL12077114 | 0.78 | PSEN1 (0.60) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL13468496 | 0.78 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL15915182 | 0.78 | MAPT (0.87) | ALDH1A1L3MBTL1HTR1AHTR7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521744-B1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | FOURNIER LAB SA (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
| EP-1521744-A1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | LABORATOIRES FOURNIER S.A. (FR) | 2005-04-13 | — | — | EP | disclosed |
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| WO-2003106428-A1 | NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATOIRES FOURNIER SA (FR) | 2003-12-24 | — | — | WO | disclosed |
| EP-1351928-A2 | NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER S.A. (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002053516-A2 | N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER SA (FR) | 2002-07-11 | — | — | WO | disclosed |
| EP-0413224-A1 | Fungicidal agent containing 1,2-naphthoquinones | BASF Aktiengesellschaft (DE) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | ALDH1A1 73/4885L3MBTL1 4830/4885HTR1A 2414/4885 |
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | ALDH1A1 2730/4885L3MBTL1 2774/4885HTR1A 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.